RESEARCH ARTICLE


Atrophosclerodermic Manifestations of Lyme Borreliosis



Elisabeth Aberer*, Nora Wutte
Department of Dermatology Medical University of Graz Auenbrugger Platz 8 A-8036 Graz, Austria


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 2152
Abstract HTML Views: 777
PDF Downloads: 197
ePub Downloads: 137
Total Views/Downloads: 3263
Unique Statistics:

Full-Text HTML Views: 1127
Abstract HTML Views: 483
PDF Downloads: 151
ePub Downloads: 103
Total Views/Downloads: 1864



© Aberer & Wutte; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Dermatology Medical University of Graz. Auenbrugger Platz 8 A-8036 Graz, Austria; Tel: 0043-316-385-13926; Fax: 0043-316-385-12466; Email: elisabeth.aberer@medunigraz.at


Abstract

This review summarizes the literature on scleratrophic skin lesions as a manifestation of a Borrelia infection. An association of morphea with Lyme borreliosis was mainly reported from Middle-European Countries, Japan and South America. B. afzelii has been identified predominantly from the chronic skin lesions of acrodermatitis chronica atrophicans (ACA) and has been cultivated from morphea lesions in isolated cases. Scleratrophic skin lesions like morphea, lichen sclerosus et atrophicus (LSA) and anetoderma have been observed in coexistence with ACA. Since all these diseases show clinical and histological similarities, they might have a common origin. The laboratory results that point to a borrelial origin of these diseases, however, are contradictory. Antibodies against B. burgdorferi were detected in up to 50% of patients. Borrelia DNA was shown in up to 33% of morphea and 50% of LSA patients. Borrelia were visualized on histological slides by polyclonal antibodies in up to 69% of morphea and 63% of LSA patients. In other reports no evidence of Borrelia – associated morphea or LSA has been reported. For anetoderma, single case reports showed positive Borrelia serology and/or PCR and a response to antibiotic treatment. The response of scleratrophic skin lesions to antibiotic treatment varies and can be seen in patients with or without a proven association to a Borrelia infection. This suggests that scleratrophic diseases might be of heterogeneous origin, but a Borrelia infection could be one cause of these dermatoses.

Keywords: B. burgdorferi sensu lato, Lyme borreliosis, Acrodermatitis chronica atrophicans, Morphea, Localized scleroderma, Lichen sclerosus et atrophicus, Meningo-radiculoneuritis, Anetoderma.



INTRODUCTION

Lyme borreliosis (LB) is a world-wide infectious disease with classical clinical manifestations in the skin, namely erythema migrans (EM) and borrelia lymphocytoma in the early and acrodermatitis chronica atrophicans (ACA) in the late stage.

In 1985 three research groups first suggested that morphea (localized scleroderma) could be another manifestation of a Borrelia burgdorferi infection [1-3]. The detailed development of research work in morphea and lichen sclerosus et atrophicus (LSA) and the association with LB was reviewed by Weide et al. in 2000 [4]. A complete summary of findings on the role of B. burgdorferi using serology, culture, PCR, immunohistochemistry, silver staining, lymphocyte stimulation test and treatment response has been published. The findings were also classified according to the respective geographic areas and countries. In 2000 and 2010, further reviews were published addressing the detection of Borrelia DNA by PCR-based methods in morphea and lichen sclerosus et atrophicus (LSA) [5, 6].

FIBROTIC CHANGES IN ACA, COEXISTENCE WITH MORPHEA AND LICHEN SCLEROSUS ET ATROPHICUS

Asbrink was one of the first to observe sclerotic changes in ACA in the context of a Borrelia infection [7]. Juxtaarticular nodules occur in 10-25% of ACA patients (Fig. 1). These can arise after the onset of ACA [8], or also as an isolated manifestation of LB (authors’ observation). There have been a number of reports of localized or widespread fibrotic lesions in B. burgdorferi infection, as well as coexistence of ACA and morphea [8-14] (Fig. 2). Among 10 seropositive morphea patients, Büchner et al. described 2 patients with a history of EM, 1 with coexisting ACA, and 2 with LSA [15]. In 1994 Trevisan et al. reviewed the association of B. burgdorferi and localized scleroderma [16].

Fig. (1).

Fibrous nodules in acrodermatitis chronica atrophicans.


Fig. (2).

Acrodermatitis chronica atrophicans with pseudoscleroderma and erythematous patches on the buttock presenting early morphea.


ACA was described in association with genital and extragenital LSA, tubulo-interstitial nephritis and spirochetes in urine that were seen one year after a tick bite [17]. ACA, LSA and nephritis regressed after antibiotic therapy.

MORPHOLOGICAL FINDINGS IN MORPHEA, LSA AND ACA

Clinically, early morphea cannot be distinguished from EM, and persisting EM cannot be distinguished from early morphea in terms of clinical or histological features in some patients. Morphea can mimic ACA as well, with a livid discoloration (Fig. 3). Whereas ACA involves acral body sites with lower temperatures, is located on the extensor surfaces of extremities and not sharply demarcated (Fig. 4), morphea is sharply demarcated, appears as single or multiple plaques that can be linear, and/or deep (including fasciitis) with possible confluence of lesions, affects any age and body site, and enlarges at the periphery of the lesions with the typical lilac ring.

Morphea is a disease of heterogeneous origin occurring after vaccination, trauma, or insect bites; it can also be congenital [18]. Histologically, the early phase is associated with edematous swelling of collagen fibers, perivascular and interstitial infiltration of lymphocytes, monocytes, histiocytes, eosinophils and plasma cells, followed by collagen overproduction or atrophy [19]. Serup divided the connective tissue changes in morphea into fibril degradation and myxedematous, cell infiltration and fibrotic stages [20]. Upon electron microscopy, collagen changes include loss of their transverse striation, disintegration of fibers, elastoid transformation and complete collagen destruction [21].

Fig. (3).

Livid patches of morphea on the trunk. Culture of a skin biopsy was positive. B. afzelii was identified by PCR-RLFP analysis [111].


Fig. (4).

Acrodermatitis with atrophic skin changes.


Histologically, ACA shows both a band-like subepidermal and a perineural cell infiltrate, atrophy of collagen with edematous or thinned collagen fibers, and fibrosis. There are no important differences between the lesional skin of ACA, fibrous nodules, ulnar bands or sclerodermatous changes [22]. Electron microscopy shows that elastic fibers are destroyed and collagen fibers are present with peripheral amorphic material in ACA [23], showing similarities to the described changes in morphea [21].

Comparing the histological features and the inflammatory infiltrate in 19 ACA and 40 morphea biopsies, histological differentiation from ACA was not possible in 17% of morphea cases regardless of positive or negative B. burgdorferi serology [24]. Both diseases display basal cytolysis of keratinocytes. In ACA the inflammatory infiltrate shows a lichenoid, in morphea a perivascular pattern. Hypertrophic basophilic elastic tissue is seen in ACA, whereas in morphea the elastic tissue is preserved and polarizing. The histological pattern of morphea could not be associated with a particular clinical type of morphea or with positive B. burgdorferi serology with exception of atrophodermia Pasini-Pierini, where an association with a Borrelia infection could not be detected in that study [25]. Thus, a Borrelia etiology cannot be established from a morphological pattern in morphea.

LSA also shows an atrophic epidermis with basal layer vacuolization [26]. The superficial dermis is edematous and hyalinized with disappearance of elastic fibers, although there is an increase in elastic fibers in the mid and lower dermis. Collagen degeneration and regeneration were observed ultrastructurally in the superficial dermis with higher amounts of ground substance [27]. Collagen fibers were also observed to be phagocytized by fibroblasts [28]. Coexistence of LSA with morphea was observed in 27 of 472 (5.7%) patients [29].

In summary, ACA, morphea and LSA share histopathological similarities like vacuolization of basal keratinocytes and loss of collagen; ACA and morphea the fibrosing tissue reaction; and ACA and LSA loss and proliferation of elastic fibers.

METHODS

A PubMed search was performed in December 2014 with the following key words: 1) “morphea, borreliosis”: 97 papers were published in the last 30 years with original publications, case series, case reports and reviews showing an association with a B. burgdorferi infection or no evidence. The majority of these publications are analyzed in this review. 2) “anetoderma, borreliosis” produced 6 papers, 4 of them case reports and 2 of them reviews pointing out that sclerotic and atrophic lesions of morphea can be observed in the spectrum of LB. 3) “atrophy, borreliosis, skin”: 26 papers were published, 14 of them about ACA, 6 about scleratrophic findings, and 3 about Parry-Romberg syndrome; there were also 3 reviews and other miscellaneous papers.

Table 1 lists research papers on morphea and LSA in relation to a Borrelia infection that have been published since 2000; Table 2 lists publications about anetoderma; and Table 3 lists clinical cases of sclerotic skin lesions that were treated with antibiotics.

Table 1.

Reports on the association of B. burgdorferi with morphea and lichen sclerosus et atrophicus since 2000.


Author, year, country No. of patients/controls Serology % pos. (pos./ no. of patients) PCR % pos (pos./ no. of patients)/primer Immuno-histochemistry % pos. (pos./ no. of patients)/used antibodies
Özkan S [5]
2000
Turkey
10 morphea 12 LSA10 controls n.d. 33% (3/10)50% (6/12) nested PCR, flagellin primer n.d
Svecova D [38]
2000
Slovakia
32 morphea7 LSA131 controls55 LB patients 34.4% (11/32) 71.4% (5/7) 33.6% (44/131)100% (55/55) n.d. n.d.
Wojas-Pelc A [39]
2002
Poland
50 morphea 28.5%
ANA 18%
n.d. n.d.
Espinoza-Leon F [55]
2006
Venezuela
21 morphea21 controls 14% (3/21) 4.7% (1/21) positive by ELISA not confirmed by IB n.d. n.d.
Sommer A [54]
2006
Germany (Bochum)
12 hemiatrophia faciei 3 positive ELISA not confirmed by IB n.d. n.d.
Eisendle K [59]
2007
Austria
122 morphea10 controls with pos PCR 58 controls with neg PCR n.d. 1/30 nested PCR B.burgdorferi 23S rRNA 69% (84/122)100% (10/10)0% (0/0) polyclonal antibodies
Eisendle K [110]
2008
Austria
60 LSA68 controls (classic LB) n.d. n.d. 63% (38/60)90% (61/68)/polyclonal antibodies, FFM
Prinz JC [40]
2009
Germany (Bavaria) Hungary
90 morphea 22% (20/90) ANA 47% (42/90) n.d. n.d.
Zollinger T [6]
2010
Switzerland
49 morphea15 LSA 48 controls (granuloma anulare) n.d. 2% (1/49)7% (1/15)2% (1/48) /nested PCR; sequence analysis: B. burgdorferi sensu stricto n.d.
Espinoza-Leon F [69]
2010
Venezuela
21 morphea n.d. 0 % (0/21) n.d.
Santos M [60]
2011
Amazonic region
15 morphea, atrophodermia Pasini-Pierini, LSA n.d. n.d. 26.6% (4/15) / FFM

EVIDENCE OF B. BURGDORFERI INFECTION IN MORPHEA (Table 1)

Serology

In the review of Weide et al. covering 1985 to 2000, a total of 138 among 609 morphea cases with positive anti-B. burgdorferi antibodies were reported from Austria, Germany, Italy, Poland, Slovakia, and Switzerland [4, 25, 30-38]. Table 1 lists the publications since 2000 that show a possible association of morphea with B. burgdorferi infection. Anti-B. burgdorferi antibodies were reported in 22 - 34.4% of morphea patients [38-40]. Wojas-Pelc et al. showed positive B. burgdorferi serology in 28.5% and positive ANA in 18% [39]. Prinz et al. observed that seropositive patients with early-onset morphea had high ANA titres [40].

Negative or negligible serologic findings were reported from Denmark, England, Finland, France, Japan, Netherlands, Spain, Venezuela, and USA [41-55].

Morphological Detection of B. burgdorferi by Immunohistochemistry or Silver Staining

In 1987 Aberer et al. detected Borrelia in 7/21 biopsies of morphea patients by immunohistochemistry. Diluted serum from an ACA patient was used and Borrelia were visualized by high-power resolution videomicroscopy [56]. In a further study Borrelia were detected in 25% of morphea, EM and ACA biopsies [57]. Borrelia could also be visualized by silver staining in 10/25 morphea patients in Puerto Rico [58], and by a polyclonal antibody in 84/122 morphea patients using focus floating microscopy (FFM) [59]. Only 1 of these 30 patients was positive by PCR. With FFM, Borrelia were detected in morphea in 3/15 patients in Brazil, LSA and atrophodermia [60] and in a case of a boy with early-onset morphea with tight skin, whereby PCR was negative [61]. Immunohistochemistry was negative in 14 morphea biopsies [47] as well as Elias-Bosma staining in 13 morphea patients [62].

PCR

In 1993 Schempp et al. showed B. burgdorferi-specific DNA with flagellin primers of the 16s-RNA gene in lesional skin of patients with morphea [48]. In a follow-up study, the results of the positive PCR were compared, since patients` biopsies were derived from 3 different countries. Whereas some of the biopsies of German and Japanese patients were positive, biopsies from the USA were negative [63]. PCR was positive in seropositive and seronegative Italian morphea patients [37]. Nested PCR was performed for Turkish morphea patients and 3/10 of them were positive [5]. Borrelia DNA was detected in different sclerodermiform skin lesions [64, 65]. Amplification of DNA sequences of B. burgdorferi by nested PCR, and proven by sequencing was only positive in 1/49 morphea patients in Switzerland [6]. No Borrelia-specific DNA has been detected in morphea lesions in several other studies from Finland, Netherlands, Spain, USA [49-51, 53, 66-69] and also in one study from Germany [33].

Culture

B. burgdorferi from skin biopsies of morphea was only cultured for a minority of patients, with low outcome [56, 70] (Fig. 3). B. afzelii was cultured from a seronegative patient with widespread morphea identified by SDS polyacrylamide-electrophoresesis of outer surface proteins [71]. Further studies culturing B. burgdorferi from morphea were negative [47, 49, 53].

Lymphocyte Transformation Test (LTT)

In 1993 Büchner et al. found significantly elevated lymphoproliferative responses in 10 seropositive morphea patients [15]. In a further study lymphoproliferative responses were measured in 45 patients with morphea compared to 21 healthy seronegative controls and patients with EM, lymphadenosis benigna cutis and ACA. Stimulation indices in morphea patients did not differ significantly from the normal population [34].

LTT was positive in a single seronegative morphea case with positive PCR by flagellin primers and immunohistochemical detection of B. burgdorferi in the skin [72]. Breier et al. reported elevated mean stimulation indices in 11/39 (28%) of seropositive and seronegative morphea patients; these were nearly as high as in patients with EM compared to ACA, seropositive LB patients and healthy controls [36].

Eosinophilic Fasciitis/Shulman Syndrome/Parry-Romberg Syndrome

Positive Borrelia serology and an association with LB were often reported in eosinophilic fasciitis/Shulman syndrome (Fig. 5) [73-78], with detection of a positive flagellin gene sequence by PCR in one patient [79]. In 4 cases of borrelial fasciitis, spirochetal organisms were identified by Dieterle and Steiner silver stains; one patient was positive with a rabbit polyclonal antibody; 2/4 patients were seropositive [80].

Fig. (5).

Eosinophilic fasciitis arising in the context of Lyme arthritis of the knee on the same extremity.


No clear association with Borrelia infection was shown in Parry-Romberg syndrome [81-83]. In a retrospective study, 2 of the 12 patients with hemiatrophy were seropositive by ELISA that was not confirmed by IB [54]. In one Italian patient with linear scleroderma “en coup de sabre” with facial atrophy, antibodies against B. burgdorferi were positive [84].

EVIDENCE OF B. BURGDORFERI INFECTION IN LICHEN SCLEROSUS ET ATROPHICUS (TABLE 1)

There are only limited studies on the determination of anti-B. burgdorferi antibodies in LSA. Svecova et al. from Slovakia found 5/7 seropositive LSA patients [38], and Aberer et al. 2/13 seropositive LSA patients [56].

Immunohistochemistry/Silver Staining

In 6/13 patients with genital and extragenital LSA, Borrelia could be detected by immunohistology after staining with a 1:20 diluted serum from a patient with high antibody titers against B. burgdorferi visualized by videomicroscopy [56]. Using FFM, Eisendle et al. detected Borrelia species in 38 of 60 cases (63%) of lichen sclerosus and in 61 of 68 (90%) positive controls of classic borreliosis, but Borrelia species were absent in all negative controls. Borrelia species were detected significantly more often in early inflammatory-rich (31 of 39 80%) than in late inflammatory-poor (7 of 21 33.3%) cases (P = .001). Polymerase chain reaction findings were positive in 25 of 68 positive controls (37%) and negative in all 11 cases of lichen sclerosus and all 15 negative controls [85].

PCR in Skin Biopsies

Özkan et al. demonstrated the presence of B. burgdorferi DNA in 6/12 patients with LSA by a nested PCR using European flagellin gene primer sets [5]. In contrast, negative molecular biological findings were reported in LSA biopsies by PCR using OspA or flagellin or clone 2H1 primers [53, 66, 67].

Zollinger et al. performed a PCR-based study and reviewed the literature. The authors could only detect Borrelia specific DNA in 1/15 (6.6%) LSA patients (1/49 morphea, 1/48 granuloma annulare) and assumed that B. burgdorferi does not play a significant role in these diseases [6].

Urine PCR

Amplification of Borrelia DNA in the urine was positive by flagellin primer in 13/19 patients with LSA (none in 23 healthy controls and 49 patients with various dermatologic diseases except in granuloma anulare in 8/13 urines [86].

Culture

Culture for B. burgdorferi was negative in 1 investigated LSA patient [53].

ATROPHIC LESIONS IN LYME BORRELIOSIS (Table 2)

Anetoderma is defined by a decreased amount of dermal elastic tissue and a variable amount of inflammatory infiltrate [87]. A patient with multiple oval skin colored macules with a wrinkled surface is reported. PCR analysis for the flagellin gene and genotyping were positive for B. afzelii. Strunk et al. reported another patient with positive IgM antibodies to B. burgdorferi and arrested progression of anetoderma after doxycycline [88].

Fig. (6).

Anetoderma at the border of an ACA lesion after antibiotic therapy.


Anetoderma was also observed with and without association to ACA proven by ELISA, IB and amplification of B. afzelii-specific DNA from skin [89]. Similarly, Bauer et al. reported anetoderma with positive PCR using the 23 S ribosomal RNA gene and increased IgG antibodies against B. burgdorferi by IB [90].

Congenital anetoderma was reported by Aberer and Weißenbacher in a newborn showing atrophic livid patches on the chest with progression in the first weeks of life. Antibodies against B. burgdorferi were negative in the baby and the mother, so LB was not proven. Treatment with ceftriaxone for 14 days stopped the progression and there was no wrinkling. Anetoderma so was not proven; the lesions rather correspond to atrophic morphea since deep structures like fat and muscle were also involved [91].

The pathogenic relationship between ACA and anetoderma is striking since the histological changes are very similar and both diseases have been described in association [89]. Atrophic wrinkled patches can remain after treatment of ACA (Fig. 6). Atrophic elastic tissue is observed among the inflammatory infiltrate in ACA, and elastic fibers, having been engulfed in HLA-DR positive cells, are HLA-DR positive [24].

Table 2.

Anetoderma in Lyme borreliosis.


Reference Diagnosis Detection method Outcome
Aberer E [91] 1997
Austria
Congenital anetoderma induced by intrauterine infection? B. burgdorferi- antibodies neg. in mother and child Complete resolution with ceftriaxone for 14 days with persisting atrophy of skin and fatty tissue, no recurrence after 8 years
Bauer J [90]
2003 Germany
Anetoderma: another facet of Lyme disease Positive PCR with 23S ribosomal RNA gene, positive B. burgdorferi IgG-antibodies Doxycycline 100mg bid 30 days; no new lesions
Hofer T [89]
2003
Switzerland
Anetoderma and LB: is there a pathogenetic relationship?
(2 patients)
B. afzelii-specific DNA, positive B. burgdorferi antibodies Improvement after doxycycline 200mg 28-30 days in both patients
Trevisan G [112]
2008
Italy
Anetoderma associated with Lyme disease Nested PCR from skin biopsy and tissue culture positive; genotyping revealed B. afzelii Penicillin G 20 Mill U/d in 4 doses 14 days; Amoxicillin bid 21 days; No further anetoderma lesions over a period of 6 months
Strunk T [88]
2011
Germany
Anetoderma with positive Borrelia serology Positive B. burgdorferi - IgM antibodies Doxycycline 100mg bid; progression arrested

CLINICAL REPORTS OF THE ASSOCIATION OF SCLEROTIC LESIONS WITH B. BURGDORFERI INFECTION AND THE EFFECT OF ANTIBIOTIC TREATMENT (Table 3)

After penicillin treatment, a seropositive patient with morphea profunda on the flexor aspects of the thigh was remarkably improved [9]. Borrelia infection was proven by detection of specific B. burgdorferi DNA and IgG antibodies in a patient with sclerodermiform skin lesions of the extremities and polyneuropathy with improvement of dermatologic and neurologic symptoms after ceftriaxone [65].

Repeated oral treatment with penicillin V and/or doxycycline for 20-30 days was effective in 6 among 30 patients with different types of morphea [25]. The lilac ring disappeared and the sclerotic plaques gradually smoothened in 8 patients treated with penicillin G 10 Mill IU intravenously bid for 14 days. Three patients unresponsive to systemic penicillin therapy responded to ceftriaxone. Two patients treated with ceftriaxone 2g for 15 days and 1 patient treated with intravenous penicillin recovered completely. All 6 seronegative patients with atrophodermia Pasini-Pierini and 1 seropositive patient with livid atrophic patches showed progression in spite of antibiotic therapy.

Wackernagel et al. reported a patient with positive ANA and CENP-B antibodies and abrupt onset of diffuse erythemas and doughy swellings involving the face and the upper trunk, followed by thickening and induration of the skin mimicking diffuse systemic scleroderma. B. burgdorferi infection was proven by repeatedly positive urine PCR and positive B. burgdorferi ELISA confirmed by IB. The patient responded rapidly to intravenous treatment with ceftriaxone 2g for 20 days [92].

Gubertini et al. observed an association of LSA, scleroderma en coup de sabre and Lyme borreliosis shown by positive PCR in the skin biopsy, blood and urine. Improvement was achieved with two courses of ceftriaxone 2g for 21 days in combination with UVA-1/vitamin E therapy [93]. Fifteen lichen sclerosus patients from the United States without evidence of a Borrelia infection were treated for 3-21 months with either intramuscular benzathin penicillin, cephalosporins, or oral antibiotics in an observational study [94]. All patients showed a significant response within a few weeks. Treatment of lichen sclerosus with either intramuscular ceftriaxone every 3 weeks or intramuscular penicillin every 2-3 weeks is recommended.

Prinz et al. observed a correlation of Borrelia-associated morphea diagnosed by serology with positive ANA [40]. Twenty of 90 patients were seropositive although some patients had only IgM antibodies, which can be interpreted as non-specific. Antibiotic treatment with penicillin G or ceftriaxone for 21 days improved sclerosis and arrested progression. As all patients had concomitant UV therapy, the effect of antibiotic treatment cannot be assessed objectively.

Table 3.

Treatment response in morphea.


Reference Clinical cases Detection method Outcome
Büchner SA [9] 1990
Switzerland
Morphea profunda Positive antibodies Penicillin; remarkable improvement
Wackernagel A [92]
2005
Austria
Acute exacerbation of SSc in Bb infection Positive PCR in urine; positive ELISA and immunoblot;genotyping B. afzelii Complete resolution after antibiotic treatment with ceftriaxone 2g for 21 days
Kaya G [113] 2001
Switzerland
Chronic borreliosis presenting with morphea- and LSA-like cutaneous lesions Positive PCR (290 bp-specific primer); positive IgM and IgG antibodies by immunoblot Ceftriaxone 2g for 21 days; improvement after 7 days
Prinz JC [40] 2009
Germany
Multiple plaques and linear morphea Positive IgM antibodies, Positive ANA Ceftriaxone 2g for 21 days + UVA 1; no further progression, no relapse, reduced sclerosis
Prinz JC [40] 2009 Germany Generalized morphea Positive IgG antibodies, positive ANA,
U1RNP-, Sm-antibodies
Penicillin G 10 mega units bid for 21 days + PUVA bath; reduction of sclerosis, relapse after 16 months
Prinz JC [40]
2009
Germany
Morphea with multiple plaques Positive IgM antibodies, Positive ANA Oral amoxicillin 500mg tid for 14 days + UVA 1; relapses
Gubertini N [93]
2011 Italy
LSA, scleroderma en coup de sabre Positive PCR in blood, tissue, urine 2 cycles ceftriaxone 2g 21 days + UVA 1 and Vit. E; improvement
Miglino B [95] 2012
Italy
Localized scleroderma unius lateri and B. burgdorferi infection Positive IgM antibodies, negative IgG antibodies Negative PCR 2 courses of benzathin penicillin 12 Mill IU/ day for 20 days; clear improvement after 4 months, softening of deep tissues

The response to antibiotic treatment in morphea and LSA is not dependent on a confirmed Borrelia infection. Borrelia DNA from peripheral blood and skin tissue was negative and only B. burgdorferi IgM antibodies were positive in a patient with left-sided painful scleratrophic plaques, progressive weakness and limb hypotrophy. After two courses of benzathin penicillin, there was clear improvement of skin lesions and softening of deep sclerotic plaques [95].

DISCUSSION

Buechner et al. suggest that ACA is a chronic T-cell mediated disease leading to severe tissue damage with atrophy of the epidermis and connective tissue [96]. Fibrosis is a typical reaction pattern seen in LB, not only in the skin but also in other tissues like the heart [22, 97]. Heart ventricles of adult Macaca mulatta monkeys show large deposits of collagen and the presence of Borrelia after inoculation with the B. burgdorferi sensu stricto N40 strain [97].

B. burgdorferi has high affinity to collagen and could be detected among collagen fibers in ACA by electron microscopy [23]. Borrelia and their degenerative products were frequently located along or between collagen bundles in morphea, partially or completely hidden if not visualized in the correct section plane as shown by FFM [59] or forming colonies in the collagen in erythema migrans, as observed by videomicroscopy [57].

This affinity of Borrelia to collagen was also shown in in vitro experiments with invasion and colonization of native type I collagen lattices [98, 99]. Binding of B. burgdorferi to adhesins such as the glucosamine-binding protein [100], fibronectin-binding protein [101, 102] and the proteoglycan decorin has been described [103]. Furthermore, B. burgdorferi possesses collagenolytic activity and plasmin-coated Borreliae degrade the extracellular matrix [104, 105]. It was suggested by Ackerman that fibrosis results mainly as a consequence of collagen destruction. Fibroblasts attempt to repair the defect but they never completely restore the original state [106]. Similarly, an increase in elastic fibers in LSA may reflect a process to repair the degraded upper dermal elastic fibers [26]. Elastic fibers are also markedly reduced in the upper and very prominent in the deeper dermis in ACA [24]. Damage of elastic and collagen fibers by B. burgdorferi has been described [107].

Laboratory methods to detect LB have to be interpreted cautiously as some test results could be misinterpreted. ELISA and IB employ different antigens and techniques that vary in their sensitivity and specificity [16], and two-tiered testing is not routine. PCR is performed with different primers to detect DNA or RNA and various sequencing methods, so that the results of these tests are hardly comparable; interpretation methods also differ. In some studies, patients were seropositive by anti - B. burgdoferi IgM antibodies only; these are not specific for a Borrelia infection when IgG seroconversion does not follow [40, 95, 108], or when the ELISA cannot be confirmed by IB [55]. The association between morphea and a Borrelia infection was reported from countries that tend to have a higher frequency of B. burgdorferi seroprevalence in the general population [16]. The results of laboratory findings and their interpretation are contradictory. When there was a small number of seropositive morphea patients, the serologic data were interpreted as a possible cross reaction, as in a paper by Hoesly et al., who reported 6/32 positive patients from the USA [109]. No Borrelia-associated morphea cases were reported in the United States. On the other hand, Granter et al. in Boston detected Borrelia in tissue sections by silver staining or by a polyclonal antibody in 4 patients with diffuse fasciitis [80].

It takes experience to identify B. burgdorferi on histological slides from among the different Borrelia forms, since the morphology of Borrelia in tissues is very heterogeneous [57]. Borrelia can only be visualized with special techniques such as videomicroscopy or focus floating microscopy, and time resources also limit this special diagnostic technique. The number of Borreliae can be very low, so that a negative finding does not rule out a Borrelia infection, and the antibodies used have different sensitivities. Borrelia can also be identified in seronegative morphea and LSA cases. Moreover, B. burgdorferi was detected immunohistochemically, not only in skin biopsies of morphea and LSA but also in several other diseases like cutaneous B-cell lymphoma, lymphocytic infiltration, granuloma anulare, interstitial granulomatous dermatitis, as well as in isolated cases of cutaneous sarcoidosis, necrobiosis lipoidica and necrobiotic xanthogranuloma [110]. The specificity of these findings remains to be determined. Borrelia can survive in different tissues and visualizing this bacterium does not always mean that it is the pathogen causing the disease.

There are significant geographic differences in the reported scleratrophic Borrelia infections, with a higher prevalence in areas of middle Europe (Fig. 7) [6]. The results of most PCR-based studies do not argue for a significant association of B. burgdorferi with morphea and LSA, and PCR was only applied in limited studies. The contradictory findings might have discouraged researchers from any further search for an infectious origin of scleratrophic skin diseases. Treatment success with antibiotics has often been reported, but controlled studies have not so far been undertaken to prove their efficacy. Pencillin G has been successfully used for therapy of dermal fibrosis. The effect of penicillin has also been attributed to a non-antibiotic action involving collagen metabolism. Yet, the mechanism of the antifibrotic action of penicillin G is still unknown [114].

Fig. (7).

World-wide reported B. burgdorferi - associated scleratrophic changes.


CONCLUSION

The sclerotic/atrophic skin changes observed in LB vary, so several differential diagnoses might be relevant and should be distinguished from the putative LB-associated diseases (Table 4).

The possible relationship between scleroatrophic skin lesions with Lyme borreliosis is supported by 1) the similar clinical appearance of morphea with EM or ACA, 2) coexistence of morphea with ACA and/or LSA in the same patient, 3) the presence of a higher percentage of antibodies than in healthy controls, 4) positive PCR, 5) identification of Borrelia on histological sections, 6) culture of B. burgdorferi from skin lesions, and 7) the response to treatment of some patients. Treatment response was also reported from morphea cases without antibodies or without another proven borrelial origin. Since morphea is a heterogenous disease, another microorganism might be causing it. It is also possible that a Borrelia infection cannot be proven because the laboratory techniques are not sensitive enough. Anetoderma can also be associated with ACA. In this rare disease, single case reports have shown anti - B. burgdorferi antibodies, positive B. burgdorferi DNA and response to antibiotic treatment.

Table 4.

Differential diagnoses of scleratrophic skin diseases.


Morphea - pseudoscleroderma Atrophic skin diseases
Granuloma anulare Granulomatous slack skin
Systemic nephrogenic fibrosis Steroid atrophy
Radiation fibrosis Neurogenic atrophy
Chronic graft-versus host disease Progeria
Lipodermatosclerosis Striae cutis distensae
Skleromyxoedema Atrophic scarring
Skleredema diabeticorum Atrophy in skin aging
Skleredema adultorum Buschke Atrophodermia vermiculata
Eosinophilia-myalgia sndrome
Toxic oil syndrome
Porphyria cutanea tarda
Progeria syndromes

There is a strong relationship between specific geographic areas with reported Borrelia-associated morphea cases and with the predominant genotype. B. afzelii was the predominant species that was isolated from ACA and B. afzelii DNA has been detected predominantly in skin lesions. Another cause for the different results in hitherto published studies is that sclerotic lesions can be misinterpreted since the pseudoscleroderma of ACA can easily be mistaken for morphea.

The pathologic changes in scleratrophic skin lesions point to connective tissues damage, which can be caused by B. burgdorferi. A high affinity of Borrelia to collagen and degradation of fibers is the central process that has not yet received attention. It can be assumed that the scleratrophic skin lesions can be caused by Borrelia infection in certain countries where B. afzelii is endemic. The response to antibiotic treatment in cases where there was no proven association to a borrelia infection suggests that other microorganisms might be involved in scleratrophic dermatoses and suggests that these diseases must be of heterogeneous origin.

To prove the Koch`s postulates, transmission experiments that have been performed in EM, ACA and lymphadenosis cutis are missing for scleratrophic skin lesions. In future controlled multicenter studies with standardized laboratory techniques including placebo-controlled treatment studies should be performed in a well-defined morphea population to determine the role of B. burgdorferi in scleratrophic skin diseases.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Aberer E, Neumann R, Stanek G. Is localised scleroderma a Borrelia infection? Lancet 1985; 2(8449): 278.
[2] Neubert U, Krampitz HE, Engl H. Microbiological findings in erythema (chronicum) migrans and related disorders. Zentralbl Bakteriol Mikrobiol Hyg A 1986; 263(1-2): 237-52.
[3] Rufli T, Lehner S, Aeschlimann A, Chamot E, Gigon F, Jeanneret JP. Enlarged spectrum of tick transmitted spirochaetoses. Hautarzt 1986; 37(11): 597-602.
[4] Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol 2000; 142(4): 636-44.
[5] Ozkan S, Atabey N, Fetil E, Erkizan V, Günes AT. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int J Dermatol 2000; 39(4): 278-83.
[6] Zollinger T, Mertz KD, Schmid M, Schmitt A, Pfaltz M, Kempf W. Borrelia in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. J Cutan Pathol 2010; 37(5): 571-7.
[7] Asbrink E. Cutaneous manifestations of Lyme borreliosis. Clinical definitions and differential diagnoses. Scand J Infect Dis Suppl 1991; 77: 44-50.
[8] Marsch WC, Mayet A, Wolter M. Cutaneous fibroses induced by Borrelia burgdorferi. Br J Dermatol 1993; 128(6): 674-8.
[9] Büchner SA, Rufli T. Morphaea profunda. Hautarzt 1990; 41(3): 155-7.
[10] Langer K, Diem E. Acrodermatitis chronic atrophicans and sclerodermiform skin changes in Borrelia infection. Hautarzt 1988; 39(10): 647-51.
[11] Coulson IH, Smith NP, Holden CA. Acrodermatitis chronica atrophicans with coexisting morphoea. Br J Dermatol 1989; 121(2): 263-9.
[12] Müller H. Acrodermatitis atrophocans arthropathica with pseudoscleroderma, circumscribed scleroderma and muscular involvement. Z Haut Geschlechtskr 1969; 44(1): 1-12.
[13] Carlesimo M, Abruzzese C, Narcisi A, et al. Acrodermatitis chronic atrophicans and morphea. Eur J Dermatol 2010; 20(3): 405-7.
[14] Ramelet AA. Association of acrodermatitis chronica atrophicans and morphea. Dermatologica 1987; 175(5): 253-6.
[15] Buechner SA, Winkelmann RK, Lautenschlager S, Gilli L, Rufli T. Localized scleroderma associated with Borrelia burgdorferi infection. Clinical, histologic, and immunohistochemical observations. J Am Acad Dermatol 1993; 29(2 Pt 1): 190-6.
[16] Trevisan G, Rees DH, Stinco G. Borrelia burgdorferi and localized scleroderma. Clin Dermatol 1994; 12(3): 475-9.
[17] Aberer E, Neumann R, Lubec G. Acrodermatitis chronica atrophicans in association with lichen sclerosus et atrophicans: tubulo-interstitial nephritis and urinary excretion of spirochete-like organisms. Acta Derm Venereol 1987; 67(1): 62-5.
[18] Kreuter A, Krieg T, Worm M, et al. AWMF Guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma. J Dtsch Dermatol Ges 2009; 7(Suppl. 6): S1-S14.
[19] Classification of circumscribed scleroderma. A multicenter study of 286 patients. The Scleroderma Study Group of the Society of Dermatologic Research. Hautarzt 1990; 41: 16-21.
[20] Serup J. Localized scleroderma (morphoea). Clinical, physiological, biochemical and ultrastructural studies with particular reference to quantitation of scleroderma. Acta Derm Venereol Suppl (Stockh) 1986; 122: 3-61.
[21] Badakov S. Elastoid transformation of the collagen fibrils in scleroderma skin. Folia Med (Plovdiv) 1992; 34(3-4): 17-21.
[22] Brehmer-Andersson E, Hovmark A, Asbrink E. Acrodermatitis chronica atrophicans: histopathologic findings and clinical correlations in 111 cases. Acta Derm Venereol 1998; 78(3): 207-13.
[23] de Koning J, Tazelaar DJ, Hoogkamp-Korstanje JA, Elema JD. Acrodermatitis chronica atrophicans: a light and electron microscopic study. J Cutan Pathol 1995; 22(1): 23-32.
[24] Aberer E, Klade H, Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am J Dermatopathol 1991; 13(4): 334-41.
[25] Aberer E, Klade H, Stanek G, Gebhart W. Borrelia burgdorferi and different types of morphea. Dermatologica 1991; 182(3): 145-54.
[26] Shiba Y, Ono K, Akiyama M, Fujimoto N, Tajima S. Increase of elastic fibers in lichen sclerosus et atrophicus. J Cutan Pathol 2014; 41(8): 646-9.
[27] Frances C, Wechsler J, Meimon G, Labat-Robert J, Grimaud JA, Hewitt J. Investigation of intercellular matrix macromolecules involved in lichen sclerosus. Acta Derm Venereol 1983; 63(6): 483-90.
[28] Mihara Y, Mihara M, Hagari Y, Shimao S. Lichen sclerosus et atrophicus. A histological, immunohistochemical and electron microscopic study. Arch Dermatol Res 1994; 286(8): 434-42.
[29] Kreuter A, Wischnewski J, Terras S, Altmeyer P, Stücker M, Gambichler T. Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol 2012; 67(6): 1157-62.
[30] Aberer E, Stanek G, Ertl M, Neumann R. Evidence for spirochetal origin of circumscribed scleroderma (morphea). Acta Derm Venereol 1987; 67(3): 225-31.
[31] Aberer E, Kollegger H, Kristoferitsch W, Stanek G. Neuroborreliosis in morphea and lichen sclerosus et atrophicus. J Am Acad Dermatol 1988; 19(5 Pt 1): 820-5.
[32] Buechner SA, Rufli T. Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients. J Am Acad Dermatol 1994; 30(3): 441-6.
[33] Wienecke R, Schlüpen EM, Zöchling N, Neubert U, Meurer M, Volkenandt M. No evidence for Borrelia burgdorferi-specific DNA in lesions of localized scleroderma. J Invest Dermatol 1995; 104(1): 23-6.
[34] Buechner SA, Lautenschlager S, Itin P, Bircher A, Erb P. Lymphoproliferative responses to Borrelia burgdorferi in patients with erythema migrans, acrodermatitis chronica atrophicans, lymphadenosis benigna cutis, and morphea. Arch Dermatol 1995; 131(6): 673-7.
[35] Kencka D, Blaszczyk M, Jabłońska S. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea. Dermatology (Basel) 1995; 190(3): 203-6.
[36] Breier P, Klade H, Stanek G, et al. Lymphoproliferative responses to Borrelia burgdorferi in circumscribed scleroderma. Br J Dermatol 1996; 134(2): 285-91.
[37] Trevisan G. Detection of Borrelia burgdorferi in skin biopsies from patients with morphea by polymerase chain reaction. J Eur Acad Dermatol Venereol 1996; 6: 15-9.
[38] Svecova D, Buchvald J. Borrelia burgdorferi antibodies in scleroderma circumscripta, lichen sclerosus et atrophicus, erythema nodosum, granuloma annulare, erythema annulare and chronic urticaria. Bratisl Lek Listy (Tlacene Vyd) 2000; 101(4): 194-9.
[39] Wojas-Pelc A, Wielowieyska-Szybińska D, Kiełtyka A. Presence of the antinuclear antibodies and antibodies to Borrelia burgdorferi among patients with morphea en plaque, deep linear scleroderma and atrophoderma Pasini-Pierini. Przegl Lek 2002; 59(11): 898-902.
[40] Prinz JC, Kutasi Z, Weisenseel P, Pótó L, Battyáni Z, Ruzicka T. “Borrelia-associated early-onset morphea”: a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. J Am Acad Dermatol 2009; 60(2): 248-55.
[41] Muhlemann MF, Wright DJ, Black C. Serology of Lyme disease. Lancet 1986; 1(8480): 553-4.
[42] Hansen K, Serup J, Høybye S. Antibodies to Borrelia burgdorferi and localised scleroderma. Lancet 1987; 1(8534): 682.
[43] Lecerf V, Bagot M, Revuz J, Touraine R, Dournon E. Borrelia burgdorferi and localized scleroderma. Arch Dermatol 1989; 125(2): 297.
[44] Lecerf V, Bagot M, Dournon E, Cosnes A, Touraine R, Revuz J. Negativity of Borrelia burgdorferi serology in scleroderma en plaques. Ann Dermatol Venereol 1989; 116(8): 539-42.
[45] Halkier-Sørensen L, Kragballe K, Hansen K. Antibodies to the Borrelia burgdorferi flagellum in patients with scleroderma, granuloma annulare and porphyria cutanea tarda. Acta Derm Venereol 1989; 69(2): 116-9.
[46] Vaillant L, Goudeau A. Localized scleroderma is not a Borrelia burgdorferi infection in France. Dermatology (Basel) 1992; 184(4): 286-8.
[47] Raguin G, Boisnic S, Souteyrand P, et al. No evidence for a spirochaetal origin of localized scleroderma. Br J Dermatol 1992; 127(3): 218-20.
[48] Schempp C, Bocklage H, Lange R, Kölmel HW, Orfanos CE, Gollnick H. Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol 1993; 100(5): 717-20.
[49] Meis JF, Koopman R, van Bergen B, Pool G, Melchers W. No evidence for a relation between Borrelia burgdorferi infection and old lesions of localized scleroderma (morphea). Arch Dermatol 1993; 129(3): 386-7.
[50] Ranki A, Aavik E, Peterson P, Schauman K, Nurmilaakso P. Successful amplification of DNA specific for Finnish Borrelia burgdorferi isolates in erythema chronicum migrans but not in circumscribed scleroderma lesions. J Invest Dermatol 1994; 102(3): 339-45.
[51] Fan W, Leonardi CL, Penneys NS. Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea). J Am Acad Dermatol 1995; 33(4): 682-4.
[52] Akimoto S, Ishikawa O, Miyachi Y. The absence of antibodies against Borrelia burgdorferi in the sera of Japanese patients with localized scleroderma. J Rheumatol 1996; 23(3): 573-4.
[53] Alonso-Llamazares J, Persing DH, Anda P, Gibson LE, Rutledge BJ, Iglesias L. No evidence for Borrelia burgdorferi infection in lesions of morphea and lichen sclerosus et atrophicus in Spain. A prospective study and literature review. Acta Derm Venereol 1997; 77(4): 299-304.
[54] Sommer A, Gambichler T, Bacharach-Buhles M, von Rothenburg T, Altmeyer P, Kreuter A. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol 2006; 54(2): 227-33.
[55] Espinoza-León F, Hassanhi-Hassanhi M, Arocha-Sandoval F, Urbina-López M. Absence of Borrelia burgdorferi antibodies in the sera of Venezuelan patients with localized scleroderma (morphea). Invest Clin 2006; 47(3): 283-8.
[56] Aberer E, Stanek G. Histological evidence for spirochetal origin of morphea and lichen sclerosus et atrophicans. Am J Dermatopathol 1987; 9(5): 374-9.
[57] Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W. Heterogeneity of Borrelia burgdorferi in the skin. Am J Dermatopathol 1996; 18(6): 571-9.
[58] Ross SA, Sánchez JL, Taboas JO. Spirochetal forms in the dermal lesions of morphea and lichen sclerosus et atrophicus. Am J Dermatopathol 1990; 12(4): 357-62.
[59] Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol 2007; 157(6): 1189-98.
[60] Santos M, Ribeiro-Rodrigues R, Talhari C, Ferreira LC, Zelger B, Talhari S. Presence of Borrelia burgdorferi “Sensu Lato” in patients with morphea from the Amazonic region in Brazil. Int J Dermatol 2011; 50(11): 1373-8.
[61] Verberkt RM, Janssen M, Wesseling J. A boy with a tight skin: Borrelia-associated early-onset morphea. Clin Exp Rheumatol 2014; 32(1): 121-2.
[62] Daoud MS, Su WP, Leiferman KM, Perniciaro C. Bullous morphea: clinical, pathologic, and immunopathologic evaluation of thirteen cases. J Am Acad Dermatol 1994; 30(6): 937-43.
[63] Fujiwara H, Fujiwara K, Hashimoto K, et al. Detection of Borrelia burgdorferi DNA (B garinii or B afzelii) in morphea and lichen sclerosus et atrophicus tissues of German and Japanese but not of US patients. Arch Dermatol 1997; 133(1): 41-4.
[64] Hercogova J. Borrelia burgdorferi: a protagonist in Lyme disease, a bystander in morphoea? J Eur Acad Dermatol Venereol 2002; 16(2): 98-9.
[65] Weidenthaler B, Roux M, Moter SE, Schulze HJ, Kramer MD. Sclerodermiform skin changes in Borrelia burgdorferi infection. Diagnostic use of polymerase chain reaction. Hautarzt 1994; 45(3): 171-5.
[66] Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 1995; 33(4): 617-20.
[67] De Vito JR, Merogi AJ, Vo T, et al. Role of Borrelia burgdorferi in the pathogenesis of morphea/scleroderma and lichen sclerosus et atrophicus: a PCR study of thirty-five cases. J Cutan Pathol 1996; 23(4): 350-8.
[68] Colomé-Grimmer MI, Payne DA, Tyring SK, Sánchez RL. Borrelia burgdorferi DNA and Borrelia hermsii DNA are not associated with morphea or lichen sclerosus et atrophicus in the southwestern United States. Arch Dermatol 1997; 133(9): 1174.
[69] Espinoza-León F, Arocha F, Hassanhi M, Arévalo J. Using the polymerase chain reaction to Borrelia burgdorferi infection in localized scleroderma injure (morphea), in Venezuelan patients. Invest Clin 2010; 51(3): 381-90.
[70] Weber K, Preac-Mursic V, Reimers CD. Spirochetes isolated from two patients with morphea. Infection 1988; 16(1): 25-6.
[71] Breier FH, Aberer E, Stanek G, Khanakaha G, Schlick A, Tappeiner G. Isolation of Borrelia afzelii from circumscribed scleroderma. Br J Dermatol 1999; 140(5): 925-30.
[72] Schempp C, Bocklage H, Owsianowski M, Lange R, Orfanos CE, Gollnick H. In vivo and in vitro detection of borrelia infection in morphea-like skin changes with negative Borrelia serology. Hautarzt 1993; 44(1): 14-8.
[73] Mosconi S, Streit M, Brönimann M, Braathen L. Eosinophilic fasciitis (Shulman syndrome). Dermatology (Basel) 2002; 205(2): 204-6.
[74] Stanek G, Konrad K, Jung M, Ehringer H. Shulman syndrome, a scleroderma subtype caused by Borrelia burgdorferi? Lancet 1987; 1(8548): 1490.
[75] Hirai K, Takemori N, Yanagawa N, Namiki M, Iizuka H, Miyamoto K. Borrelia burgdorferi and Shulman syndrome. Lancet 1992; 340(8833): 1472.
[76] Belot V, Mulleman D, Perrinaud A, Abdallah-Lotf M, Machet MC, Machet L. Eosinophilic fasciitis associated with Borrelia burgdorferi infection. Ann Dermatol Venereol 2007; 134(8-9): 673-7.
[77] Sepp N, Schmutzhard E, Fritsch P. Shulman syndrome associated with Borrelia burgdorferi and complicated by carpal tunnel syndrome. J Am Acad Dermatol 1988; 18(6): 1361-2.
[78] Ferradini L, Bagot M, Roujeau JC, Touraine R. Borrelia burgdorferi and Shulman syndrome. Lancet 1987; 2(8559): 624.
[79] Hashimoto Y, Takahashi H, Matsuo S, et al. Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology (Basel) 1996; 192(2): 136-9.
[80] Granter SR, Barnhill RL, Duray PH. Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol 1996; 18(5): 465-73.
[81] Stern HS, Elliott LF, Beegle PH Jr. Progressive hemifacial atrophy associated with Lyme disease. Plast Reconstr Surg 1992; 90(3): 479-83.
[82] Baskan EB, Kaçar SD, Turan A, Saricaoglu H, Tunali S, Adim SB. Parry-Romberg syndrome associated with borreliosis: could photochemotherapy halt the progression of the disease? Photodermatol Photoimmunol Photomed 2006; 22(5): 259-61.
[83] Sahin MT, Bariş S, Karaman A. Parry-Romberg syndrome: a possible association with borreliosis. J Eur Acad Dermatol Venereol 2004; 18(2): 204-7.
[84] Salpietro DC, Merlino MV, Bruglia S, Guarneri F, Vaccaro M. Linear scleroderma ‘en coup de sabre’ associated with facial atrophy in a patient seropositive for Borrelia burgdorferi: a true case of molecular mimicry? Pediatr Allergy Immunol 2004; 15(6): 570-2.
[85] Eisendle K, Grabner T, Kutzner H, Zelger B. Possible role of Borrelia burgdorferi sensu lato infection in lichen sclerosus. Arch Dermatol 2008; 144(5): 591-8.
[86] Aberer E, Schmidt BL, Breier F, Kinaciyan T, Luger A. Amplification of DNA of Borrelia burgdorferi in urine samples of patients with granuloma annulare and lichen sclerosus et atrophicus. Arch Dermatol 1999; 135(2): 210-2.
[87] Trevisan G, Padovan C, Scaini MT, Cinco M, Floris R, Bonin S. Anetoderma associated with lyme disease: a case report. Acta Derm Venereol 2008; 88(5): 536-8.
[88] Strunk T, Hetzer S, Homey B, Reifenberger J. Anetoderma with positive Borrelia serology. Hautarzt 2011; 62(10): 720-2.
[89] Hofer T, Goldenberger D, Itin PH. Anetoderma and borreliosis: is there a pathogenetic relationship? Eur J Dermatol 2003; 13(4): 399-401.
[90] Bauer J, Leitz G, Palmedo G, Hügel H. Anetoderma: another facet of Lyme disease? J Am Acad Dermatol 2003; 48(5)(Suppl.): S86-8.
[91] Aberer E, Weissenbacher G. Congenital anetoderma induced by intrauterine infection? Arch Dermatol 1997; 133(4): 526-7.
[92] Wackernagel A, Bergmann AR, Aberer E. Acute exacerbation of systemic scleroderma in Borrelia burgdorferi infection. J Eur Acad Dermatol Venereol 2005; 19(1): 93-6.
[93] Gubertini N, Bonin S, Trevisan G. Lichen sclerosus et atrophicans, scleroderma en coup de sabre and Lyme borreliosis. Dermatol Rep 2011; 3(2): e27.
[94] Shelley WB, Shelley ED, Amurao CV. Treatment of lichen sclerosus with antibiotics. Int J Dermatol 2006; 45(9): 1104-6.
[95] Miglino B, Viana M, Zavattaro E, Bonin S, Valente G, Colombo E. Localized scleroderma unius lateri and Borrelia burgdoferi infection. Indian J Dermatol Venereol Leprol 2012; 78(3): 383-5.
[96] Buechner SA, Rufli T, Erb P. Acrodermatitis chronic atrophicans: a chronic T-cell-mediated immune reaction against Borrelia burgdorferi? Clinical, histologic, and immunohistochemical study of five cases. J Am Acad Dermatol 1993; 28(3): 399-405.
[97] Cadavid D, Bai Y, Hodzic E, Narayan K, Barthold SW, Pachner AR. Cardiac involvement in non-human primates infected with the Lyme disease spirochete Borrelia burgdorferi. Lab Invest 2004; 84(11): 1439-50.
[98] Zambrano MC, Beklemisheva AA, Bryksin AV, Newman SA, Cabello FC. Borrelia burgdorferi binds to, invades, and colonizes native type I collagen lattices. Infect Immun 2004; 72(6): 3138-46.
[99] Cabello FC, Godfrey HP, Newman SA. Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix. Trends Microbiol 2007; 15(8): 350-4.
[100] Parveen N, Leong JM. Identification of a candidate glycosaminoglycan-binding adhesin of the Lyme disease spirochete Borrelia burgdorferi. Mol Microbiol 2000; 35(5): 1220-34.
[101] Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50(8): 2660-6.
[102] Brissette CA, Bykowski T, Cooley AE, Bowman A, Stevenson B. Borrelia burgdorferi RevA antigen binds host fibronectin. Infect Immun 2009; 77(7): 2802-12.
[103] Liang FT, Brown EL, Wang T, Iozzo RV, Fikrig E. Protective niche for Borrelia burgdorferi to evade humoral immunity. Am J Pathol 2004; 165(3): 977-85.
[104] Grab DJ, Kennedy R, Philipp MT. Borrelia burgdorferi possesses a collagenolytic activity. FEMS Microbiol Lett 1996; 144(1): 39-45.
[105] Coleman JL, Roemer EJ, Benach JL. Plasmin-coated borrelia Burgdorferi degrades soluble and insoluble components of the mammalian extracellular matrix. Infect Immun 1999; 67(8): 3929-36.
[106] Ackerman AB. Fibrosing Dermatitis. In: Histologic Diagnosis of inflammatiory skin diseases. Philadelphia: Lea & Febinger, Henry Kimpton Publishers 1978; p. 715.
[107] Müller KE. Damage of collagen and elastic fibres by borrelia burgdorferi-known and new clinical and histopathological aspects. Open Neurol J 2012; 6: 179-86.
[108] Weber K. Is juvenile localized scleroderma related to Lyme borreliosis? J Am Acad Dermatol 2009; 61(5): 901.
[109] Hoesly JM, Mertz LE, Winkelmann RK. Localized scleroderma (morphea) and antibody to Borrelia burgdorferi. J Am Acad Dermatol 1987; 17(3): 455-8.
[110] Eisendle K, Zelger B. The expanding spectrum of cutaneous borreliosis. G Ital Dermatol Venereol 2009; 144(2): 157-71.
[111] Aberer E, Dekan G, Mayr Kanhäuser S, Aberer W. Extravascular necrotizing granuoma induced by mineral wool in circumscribed scleroderma lesions. Exogenous Dermatol 2002; 1: 253-9.
[112] Trevisan G, Padovan C, Scaini MT, Cinco M, Floris R, Bonin S. Anetoderma associated with lyme disease: a case report. Acta Derm Venereol 2008; 88(5): 536-8.
[113] Kaya G, Berset M, Prins C, Chavaz P, Saurat JH. Chronic borreliosis presenting with morphea-and lichen sclerosus et atrophicus-like cutaneous lesions. a case report. Dermatology (Basel) 2001; 202(4): 373-5.
[114] Anderegg U, Wilczek A, Haustein UF. Penicillin G does not alter collagen type I metabolism of dermal fibroblasts in culture. Dermatology (Basel) 2000; 200(2): 111-4.